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Methodology. Seventeen patients with prostate-specific antigen (PSA) rise following local treatment for prostate cancer with
curative intent underwent open orminimally invasive salvage pelvic lymph node dissection (SLND) for oligometastatic disease (<4
synchronous metastases) or as staging prior to salvage radiotherapy. Biochemical recurrence after complete biochemical response
(cBR)was defined as 2 consecutive PSA increases>0,2 ng/mL; and after incomplete biochemical response as 2 consecutive PSA rises.
Newly foundmetastasis on imaging defined clinical progression (CP). Palliative androgen deprivation therapy (ADT) was initiated
if >3 metastases were detected or if patients became symptomatic. Kaplan-Meier statistics were applied. Results. Clavien-Dindo
grade 1, 2, 3a, and 3b complications were seen in 6, 1, 1, and 2 patients, respectively. Median follow-up time was 22 months. Among
13 patients treated for oligometastatic disease, 8 (67%) had a PSA decline, with 3 patients showing cBR. Median PSA progression-
free survival (FS) was 4.1 months and median CP-FS 7 months. Three patients started ADT, resulting in a 2-year ADT-FS rate of
79.5%.Conclusion. SLND is feasible, but postoperative complication rate seems higher than that for primary LND. Biochemical and
clinical response duration is limited, but as part of an oligometastatic treatment regime it can defer palliative ADT.
1. Introduction and Objectives
Primary treatments for localized prostate cancer (PC) are
provided for optimistic oncological results, with even high-
risk patients obtaining a 10-year cancer specific survival of
90% [1]. However, these outcomes are accompanied by a
significant number of patients presenting with biochemical
recurrence after primary treatment, indicating the presence
of prostatic epithelial tissue. These 20–50% of cases that do
progress with a rise in PSA might show reduced cancer-
specific survival rates [2–4]. Advanced imaging techniques,
such as magnetic resonance imaging (MRI) and choline
positron emission tomography (PET) combined with com-
puted tomography (CT), aim to detect recurrent disease in as
early as possible stage [5].
Within this group large differences exist in clinical pro-
gression patterns and survival rates. Several groups recently
demonstrated the prognostic importance of the site of
recurrence, favoring nodal disease with a better outcome as
compared to osseous or visceral spread [6, 7]. Furthermore,
limited spread of disease, often referred to as oligometastatic
disease, has also been associated with better oncological
prognosis [6, 8, 9].
In the past nonlocalized PCwas often initially treated sys-
temically, mainly by means of androgen deprivation therapy
(ADT). These treatments can cause an important decrease in
quality of life, are not curative, andmay eventually lead to cas-
tration resistant disease requiring further systemic treatment
[10]. A nonsystemic treatment such as salvage lymph node
dissection (SLND) might be able to halt further recurrence,
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whilst deferring systemic treatment [11]. Results from several
SLND series show the possibility of a biochemical response
after surgery, although its duration may vary [12–17]. On the
downside, reported complication rates may have a significant
impact on quality of life [16, 18].
In this light, we present our series of SLND, performed
mostly with minimally invasive surgical techniques, in which
we weigh the surgical morbidity against a potential oncologi-
cal benefit, without the effect of adjuvant therapies.This paper
further aims to describe the possibility of delaying systemic
therapy within this patient group.
2. Materials and Methods
2.1. Patient Selection. Between June 2009 and June 2014, 17
patients underwent SLND at our institution. Indications for
SLND were treatment of oligometastatic PC recurrence (<4
synchronous metastases) as visualized on standard CT with
additional bone scan, fluorodeoxyglucose- (FDG-) PET-CT
(𝑛 = 7), or choline PET-CT (𝑛 = 6) or staging prior to salvage
prostate bed (pN0) or whole-pelvis (pN1) radiotherapy (𝑛 =
4). Median preoperative PSA was 2,01 ng/mL (range 0,24–
26,5). The study was approved by the local ethics committee
(EC UZG 2011/495).
2.2. Surgical Details. Surgery was performed open (𝑛 = 4),
transperitoneally laparoscopic (𝑛 = 7), or robot-assisted
(𝑛 = 6) by 2 surgeons (N.L. and K.D.C.). SLND template was
bilaterally extended in 13 patients, including 4 patients with
additional removal of suspicious lymph nodes (LNs) outside
this template (presacral and para-aortic nodes), unilaterally
extended in 1 patient, and limited to suspicious LNs on
imaging in 3 patients. Extended SLND includes removal of
all fatty, fibrous, and lymphatic tissue medially from the
lateral border of the external iliac artery, laterally from the
hypogastric artery, from the obturator fossa with complete
deskeletonization of the obturator nerve, caudally up to and
including the node of Cloquet, and cranially up to the cross-
ing of the ureter over the common iliac artery. Titanium clips
were used to seal distal lymphatic vessels before transection
[19]. Finally, one drainwas placed on each operated side in the
obturator fossa and was usually removed when it produced
<100mL over 24 h. Standard thromboembolic prophylaxis
comprised early mobilization, compression stockings, and
14 days of LMWH injected in the upper arm [19]. Sampled
LNs from each specimen were fixed overnight in 4% buffered
formalin, processed for paraffin embedding, and cut into
2 𝜇m thick sections. All sections underwent hematoxylin-
eosin staining and microscopic evaluation by two urological
pathologists.
2.3. Data Collection. Data on patient and tumor character-
istics, surgery, and pathology were gathered prospectively.
Complications were recorded during hospitalization and on
follow-up visits (at least one within the first postoperative
month). All patients had PSA measurement within 40 days
following surgery and at intervals of 3 months thereafter.
Imaging was performed at the treating physician’s discre-
tion. Postoperative complications were graded according
to Clavien-Dindo classification [20]. A lymphocele was
considered symptomatic when it caused local pain, fever,
bladder neck obstruction, or thromboembolism or if the
patient suffered lymphorrhea >5 days through the drain
or percutaneous. Complete biochemical response (cBR) fol-
lowing SLND was defined as PSA < 0,2 ng/mL within 40
days postoperatively, whereas incomplete response (iBR) was
defined as PSA > 0,2 ng/mL. Nonresponders did not show a
drop in PSA. After cBR, biochemical recurrence was defined
as an increase in PSA > 0,2 ng/mL on 2 consecutive measure-
ments. After iBR, 2 consecutive PSA rises were considered as
biochemical progression [13]. PSA progression was reached
when either biochemical recurrence or progression was seen.
At least one new metastatic site on postoperative imaging
was defined as clinical progression (CP). Palliative androgen
deprivation therapy (ADT) was initiated if >3 metastases
were detected or if patients became symptomatic.
2.4. Statistical Analysis. All statistical analyses were per-
formed using SPSS version 22.0 (IBM, Armonk, NY, USA).
Values are presented as median (range). Kaplan-Meier statis-
tics were applied to determine PSA progression-, CP- and
ADT-free survival (FS). Kaplan-Meier graphs were produced
using MEdCalc, version 14.10 (MEdCalc Software, Oostende,
Belgium).
3. Results
Patient and tumor characteristics are described in further
detail in Table 1. For the analysis of surgical outcomes all 17
patients were included. To evaluate the oncological outcome
of SLND only patients that did not undergo SLND as part of
a diagnostic work-up before salvage radiation therapy were
regarded (𝑛 = 13).
3.1. Surgical Outcome (𝑛 = 17, Tables 2 and 3). 11 nodes
as a median were resected (range 1–21), with 15 patients
having histopathological confirmation of LN involvement.
Median follow-up time was 22 months (range 4–61). Two
laparoscopic interventions were converted to open surgery
because of extensive adhesions. Grade 1, 2, 3a, and 3b
complications were seen in 6 (33%), 1 (6%), 1 (6%), and 2
(11%) patients, respectively. Three patients suffered transient
penile or scrotal edema, 2 had a temporary loss of sensa-
tion in the genitofemoral nerve dermatome, and 1 showed
prolonged ileus after surgery (grade 1). Of those requiring
further treatment, one patient was admitted for antibiotic
treatment because of a hospital-acquired pneumonia (grade
2) and 3 patients underwent additional interventions to cope
with surgical complications: one patient had a percutaneous
drainage of a lymphocele and received anticoagulants for a
deep venous thrombosis (grade 3a); another presented with
partial bladder necrosis demanding transurethral resection;
finally a lymphocele with abscedation needed to be surgically
drained under general anesthesia (grade 3b). All of grade 3a
or 3b complications were reported after open SLND.
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Table 1: Patient and tumor characteristics for all patients and patients in oncological follow-up.
All patients (surgical follow-up) (𝑛 = 17) Oncological follow-up (𝑛 = 13)
Median age, years (range) 65 (48–77) 65 (48–77)
Median body mass index, kg/m2 (range) 28,9 (23,3–32,7) 24,7 (23,3–32,7)
Median PSA at diagnosis, ng/mL (range) 12 (5,2–38) 12 (5,9–38)
Gleason score, 𝑛 (%)
6 1 (6) 1 (8)
7 (3 + 4) 5 (29) 4 (31)
7 (4 + 3) 3 (18) 2 (15)
8 5 (29) 4 (31)
9 3 (18) 2 (15)
10 — —
Clinical tumor stage, 𝑛 (%)
T2 6 (35) 5 (38)
T3a 4 (24) 4 (31)
T3b 3 (18) 1 (8)
T4 1 (6) 1 (8)
Unknown 3 (18) 2 (15)
Primary treatment, 𝑛 (%)
Surgery 14 (82) 11 (85)
Radiotherapy 2 (12) 2 (15)
High-intensity, focused ultrasound 1 (6) —
Previous PLND, 𝑛 (%) 5 (29) —
Median PSA at SLND, ng/mL (range) 2,01 (0,24–26,54) 2,01 (0,69–26,54)
Median PSAdt at SLND, months (range) 5,3 (1,5–46,5) 5,1 (1,6–19,8)
Median follow up, months (range) 22 (4–60) 21 (4–60)
∗PSA = prostate specific antigen; PSAdt = PSA doubling time; PLND = pelvic lymph node dissection; SLND = salvage pelvic lymph node dissection.
3.2. Oncological Outcome (𝑛 = 13). Among the 13 pa-
tients treated for oligometastatic disease, all but one with
histopathological LN involvement, 9 (69%) had a postopera-
tive PSA decline, including 3 patients (23%) that showed cBR
(Figure 1). Median follow-up was 21 months (range 4–60)
in the oncological group. Median PSA progression-FS was
4.1 months (range 0–20). Eight patients (54%) showed CP:
1 solely to pelvic LNs outside SLND template, 1 to pelvic LNs
outside SLND template and to the bone, 3 to retroperitoneal
LNs, 1 to the bone, 1 to the penile spongious body, and 1 to
the abdominal wall. Median CP-FS was 7 months (range 3–
38). Of patients without clinical progression, 3 still have cBR
and 2 showed biochemical recurrence. Five (38%) and 1 (8%)
patients were treated with 1 and 2 additional oligometastasis-
directed therapies, respectively. These include surgical resec-
tion of a metastasis in the penile spongious body and of
an abdominal wall mass, stereotactic body radiation therapy
(SBRT) to a vertebral lesion, SBRT for a bone lesion with a
synchronous positive pelvic LN, and three times SBRT for
positive LNs (both pelvic and para-aortic). Three patients
(23%) started palliative ADT, resulting in a projected 2-year
ADT-FS rate of 79.5% (Figure 2).
4. Discussion
4.1. Surgical Outcome. The surgical complication rate of this
series of SLND is far from trivial, with 59% of patients
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Figure 1: Percentual change in PSA within 40 days postoperatively,
in patients treated for oligometastatic disease.
reporting adverse events, even though most of them are
grade 1 as defined by the Clavien-Dindo classification. This
is in accordance with other series of SLND reporting overall
complication rates ranging from 0 to 90% [13, 15, 16, 21].
The most frequently reported complications in literature are
lymphorrhea, fever, and prolonged ileus. The only reported
grade 3b complication was a lymphocele requiring surgical
drainage, as described by Suardi et al. [16] We can thus
conclude that both the pattern and the frequency of adverse
events we report here are consistent with other series.
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Table 2: Surgical details (𝑛 = 17).
Surgical approach
4 (24%) Open
7 (41%) Laparoscopic
6 (35%) Robot-assisted
Resected nodes
Total number of resected nodes 200
Total number of positive nodes 39
Number of resected nodes/patient (median, range) 11 (1–21)
Number of positive nodes/patient (median, range) 1 (0–6)
Distribution of nodes (%) Resected (n = 200) Positive (n = 39)
Common iliac nodes 5% 5%
Internal iliac nodes 19% 23%
External iliac nodes 42% 38%
Obturator nodes 31% 18%
Presacral nodes 3% 3%
Para-aortic nodes 1% 3%
Pararectal nodes 2% 10%
SLND indication 13 (76%) Treatment of oligometastatic disease
4 (24%) Staging prior to salvage radiotherapy
Table 3: Surgical complications according to Clavien-Dindo classification (𝑛 = 17).
None 7 (41%) —
Grade 1 6 (35%) Transient penile/scrotal lymphedema: no treatment 3
Sensitivity loss, inner thigh (genitofemoral nerve) 2
Prolonged ileus 1
Grade 2 1 (6%) Pneumonia (antibiotics) 1
Grade 3a 1 (6%) Deep venous thrombosis due to lymphocele: percutaneous drainage + anticoagulants 1
Grade 3b 2 (12%) Partial bladder necrosis: transurethral resection 1
Abcedated lymphocele: surgical fenestration and drainage 1
ADT free survival (n = 13)
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Figure 2: Post-SLND ADT-free survival among patients treated for
oligometastatic disease (𝑛 = 13). Projected 2-year ADT-FS is 79.5%.
Noteworthy is the fact that this is the first prospective series
to date reporting surgical and oncological outcomes of SLND
performed mostly with minimal invasive techniques. All of
our grade 3a and 3b complications were seen after open
SLND, hinting that the use of minimally invasive techniques
might reduce surgical morbidity in this setting, including
wound dehiscence and prolonged ileus. More, larger and
comparative series are needed to determine the optimal
SLND approach.
Notably, complications seem to be more frequent in
the salvage setting than in the primary treatment setting.
We recently published data on surgical complications of
PLNDperformedby the same surgeons prior to radiotherapy:
primary staging PLND had an overall complication rate of
25%, with 11%, 2%, 4%, and 5% grade 1, 2, 3a, and 3b events
[22]. The 2- to 3-fold higher complication rate following
SLNDmight be attributed to previous pelvic treatment (both
surgery and/or radiation therapy) causing local fibrosis and
blurring surgical landmarks.
4.2. Oncological Outcome. In our series, median time to
biochemical recurrence (after complete PSA response) or
progression (after incomplete PSA response) was only 4.1
months.Of other published series, only the group of complete
responders of Jilg et al. can be compared to this group
since these patients also did not receive adjuvant ADT and
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since the same biochemical cutoffs were used. They report a
median time to biochemical progression and recurrence of
9,8 and 16,7 months, respectively, but it is unclear whether
this group received adjuvant radiation therapy or not [13].
We report a median clinical progression-free survival of 7
months without adjuvant therapy, whereas other series report
15 to 60 months until clinical progression, but with adjuvant
therapy [13, 16, 21]. We succeeded in our aim of deferring
systemic treatment, as ADT was only initiated in 3 patients.
The projected ADT-FS at 2 years is 78.5%, which exceeds
other oligometastatic treatment regimes with stereotactic
body radiation therapy, showing a 2-year ADT-FS of 50%
[23]. Deferring systemic treatment might improve overall
quality of life, but the final oncological effects are yet to
be shown. However, several trials are being conducted to
clarify these outcomes (NCT01558427, NCT01777802, and
NCT01859221).
Our cohort represents a diverse group of patients with
heterogeneous primary histology (Gleason 6–9) and PSA
levels at the time of SLND ranging from 0,69 to 26,54 ng/mL.
On this matter, patients with lower PSA and a Gleason score
below 8 at radical prostatectomymight have a better outcome
than others after SLND [13, 16, 24]. Better patient selection
might improve oncological outcome of SLNDandwould only
expose those patients that might have a substantial benefit to
the possible surgical morbidity.
5. Conclusions
This series presents surgical and early oncological results
after SLND without the effect of any adjuvant therapies,
be it ADT or radiation therapy. SLND for oligometastatic
PC recurrence seems feasible, both open and minimally
invasive, but postoperative complication rate is rather high as
compared to primary PLND series. Although only a limited
number of patients had a durable biochemical response,
as part of an oligometastatic treatment regime it can defer
palliative ADT. Larger, prospective trials are needed for
further clarification of these results.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
TomClaeys and Charles Van Praet contributed equally to the
paper.
References
[1] A. Heidenreich, P. J. Bastian, J. Bellmunt et al., “EAU guidelines
on prostate cancer. Part 1: screening, diagnosis, and local treat-
ment with curative intent—update 2013,” EuropeanUrology, vol.
65, no. 1, pp. 124–137, 2014.
[2] S. J. Freedland, E. B. Humphreys, L. A. Mangold et al., “Risk
of prostate cancer-specific mortality following biochemical
recurrence after radical prostatectomy,” Journal of the American
Medical Association, vol. 294, no. 4, pp. 433–439, 2005.
[3] S. A. Boorjian, R. H. Thompson, M. K. Tollefson et al., “Long-
term risk of clinical progression after biochemical recurrence
following radical prostatectomy: the impact of time from
surgery to recurrence,”EuropeanUrology, vol. 59, no. 6, pp. 893–
899, 2011.
[4] M. N. Simmons, A. J. Stephenson, and E. A. Klein, “Natural
history of biochemical recurrence after radical prostatectomy:
risk assessment for secondary therapy,” European Urology, vol.
51, no. 5, pp. 1175–1184, 2007.
[5] L. Evangelista, F. Zattoni, A. Guttilla, G. Saladini, P. M. Colletti,
and D. Rubello, “Choline PET or PET/CT and biochemical
relapse of prostate cancer: a systematic review and meta-
analysis,” Clinical Nuclear Medicine, vol. 38, no. 5, pp. 305–314,
2013.
[6] P. Ost, K. Decaestecker, B. Lambert et al., “Prognostic factors
influencing prostate cancer-specific survival in non-castrate
patients with metastatic prostate cancer,” The Prostate, vol. 74,
no. 3, pp. 297–305, 2014.
[7] G. R. Pond, G. Sonpavde, R. de Wit, M. A. Eisenberger, I. F.
Tannock, and A. J. Armstrong, “The prognostic importance
of metastatic site in men with metastatic castration-resistant
prostate cancer,” European Urology, vol. 65, no. 1, pp. 3–6, 2014.
[8] D. Singh, W. S. Yi, R. A. Brasacchio et al., “Is there a favorable
subset of patients with prostate cancer who develop oligometas-
tases?” International Journal of Radiation Oncology Biology
Physics, vol. 58, no. 1, pp. 3–10, 2004.
[9] M. T. Schweizer, X. C. Zhou, H. Wang et al., “Metastasis-
free survival is associated with overall survival in men with
PSA-recurrent prostate cancer treated with deferred androgen
deprivation therapy,” Annals of Oncology, vol. 24, no. 11, Article
ID mdt335, pp. 2881–2886, 2013.
[10] L. G. Taylor, S. E. Canfield, and X. L. Du, “Review of major
adverse effects of androgen-deprivation therapy in men with
prostate cancer,” Cancer, vol. 115, no. 11, pp. 2388–2399, 2009.
[11] P. Berkovic, G. deMeerleer, L. Delrue et al., “Salvage stereotactic
body radiotherapy for patients with limited prostate cancer
metastases: deferring androgen deprivation therapy,” Clinical
Genitourinary Cancer, vol. 11, no. 1, pp. 27–32, 2013.
[12] P. Rigatti, N. Suardi, A. Briganti et al., “Pelvic/retroperitoneal
salvage lymph node dissection for patients treated with radical
prostatectomy with biochemical recurrence and nodal recur-
rence detected by [11C]choline positron emission tomogra-
phy/computed tomography,” European Urology, vol. 60, no. 5,
pp. 935–943, 2011.
[13] C. A. Jilg, H. C. Rischke, S. N. Reske et al., “Salvage lymph node
dissection with adjuvant radiotherapy for nodal recurrence of
prostate cancer,” Journal of Urology, vol. 188, no. 6, pp. 2190–
2197, 2012.
[14] A. Winter, J. Uphoff, R.-P. Henke, and F. Wawroschek, “First
results of [11C]choline PET/CT-guided secondary lymph node
surgery in patients with PSA failure and single lymph node
recurrence after radical retropubic prostatectomy,” Urologia
Internationalis, vol. 84, no. 4, pp. 418–423, 2010.
[15] L. Rinnab, F. M. Mottaghy, J. Simon et al., “[11C]choline
PET/CT for targeted salvage lymph node dissection in patients
with biochemical recurrence after primary curative therapy for
prostate cancer: preliminary results of a prospective study,”
Urologia Internationalis, vol. 81, no. 2, pp. 191–197, 2008.
[16] N. Suardi, G. Gandaglia, A. Gallina et al., “Long-term out-
comes of salvage lymph node dissection for clinically recurrent
6 BioMed Research International
prostate cancer: results of a single-institution series with a
minimum follow-up of 5 years,” European Urology, 2014.
[17] F. Abdollah, R. J. Karnes, N. Suardi et al., “Predicting survival
of patients with node-positive prostate cancer following multi-
modal treatment,” European Urology, vol. 65, no. 3, pp. 554–562,
2014.
[18] F. Abdollah, A. Briganti, F. Montorsi et al., “Contemporary
role of salvage lymphadenectomy in patients with recurrence
following radical prostatectomy,” European Urology, 2014.
[19] A. Heidenreich, “Guidelines and counselling for treatment
options in the management of prostate cancer,” Recent Results
in Cancer Research, vol. 175, pp. 131–162, 2007.
[20] D. Dindo, N. Demartines, and P.-A. Clavien, “Classification
of surgical complications: a new proposal with evaluation in
a cohort of 6336 patients and results of a survey,” Annals of
Surgery, vol. 240, no. 2, pp. 205–213, 2004.
[21] J. Busch, S. Hinz, C. Kempkensteffen et al., “Selective lymph
node dissection for castration-resistant prostate cancer,” Urolo-
gia Internationalis, vol. 88, no. 4, pp. 441–446, 2012.
[22] C. Van Praet, K. Decaestecker, V. Fonteyne et al., “Contempo-
raryminimally-invasive extended pelvic lymph node dissection
for prostate cancer before curative radiotherapy: prospective
standardized analysis of complications,” International Journal of
Urology, vol. 21, no. 11, pp. 1138–1143, 2014.
[23] K. Decaestecker, G. de Meerleer, B. Lambert et al., “Repeated
stereotactic body radiotherapy for oligometastatic prostate
cancer recurrence,” Radiation Oncology, vol. 9, article 135, 2014.
[24] T. Martini, R. Mayr, E. Trenti et al., “The role of 11C-choline-
PET/CT-guided secondary lymphadenectomy in patients with
PSA failure after radical prostatectomy: lessons learned from
eight cases,” Advances in Urology, vol. 2012, Article ID 601572, 4
pages, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
